A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes

Experimental Physiology

Volumn 99, Issue 5, 2014, Pages 802-815

  Zhang, Jiandong ^a   Gu, Chunyan ^a   Lawrence, Daniel A ^b   Cheung, Alfred K ^a,c   Huang, Yufeng ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DESMIN; GLUCOSE; MESSENGER RNA; NEPHRIN; OCCLUDIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; TRANSFORMING GROWTH FACTOR BETA1; B7 ANTIGEN; PROTEIN ZO1; TJP1 PROTEIN, RAT;

ALBUMINURIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROTECTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; MORPHOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEINURIA; THERAPY EFFECT; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY;

ALBUMINURIA; ANIMALS; ANTIGENS, CD80; CELLS, CULTURED; DESMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; MALE; MICE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCYTES; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84899928632     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2013.077610     Document Type: Article

References (49)

1. Abbas AK & Sharpe AH (1999). T-cell stimulation: an abundance of B7s. Nat Med 5, 1345-1346.
2. Abramoff MD, Magelhaes PJ & Ram SJ (2004). Image processing with ImageJ. Biophoton Int 11, 36-42.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z & Shahinfar S (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, 861-869.
4. Brown NJ (2010). Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 4, 315-324.
5. Chambers CA & Allison JP (1999). Costimulatory regulation of T cell function. Curr Opin Cell Biol 11, 203-210.
6. Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S & Eddy AA (2006). Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 104, e23-e34.
7. Eddy AA & Fogo AB (2006). Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17, 2999-3012.
8. Fornoni A (2010). Proteinuria, the podocyte, and insulin resistance. N Engl J Med 363, 2068-2069.
9. Ghosh AK & Vaughan DE (2012). PAI-1 in tissue fibrosis. J Cell Physiol 227, 493-507.
10. Grandaliano G, Gesualdo L, Ranieri E, Monno R & Schena FP (2000). Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. Am J Kidney Dis 35, 726-738.
11. Huang Y, Border WA, Lawrence DA & Noble NA (2006). Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int 70, 515-522.
12. Huang Y, Border WA, Lawrence DA & Noble NA (2009). Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol 297, F1045-F1054.
13. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA & Noble NA (2008). A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19, 329-338.
14. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L & Noble NA (2003). A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112, 379-388.
15. Huang Y & Noble NA (2007). PAI-1 as a target in kidney disease. Curr Drug Targets 8, 1007-1015.
16. Huang Y, Noble NA, Zhang J, Xu C & Border WA (2007). Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72, 45-52.
17. Kawachi H, Miyauchi N, Suzuki K, Han GD, Orikasa M & Shimizu F (2006). Role of podocyte slit diaphragm as a filtration barrier. Nephrology 11, 274-281.
18. Keeton M, Eguchi Y, Sawdey M, Ahn C & Loskutoff DJ (1993). Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 142, 59-70.
19. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR & Tipping PG (2003). Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 14, 1487-1495.
20. Knier B, Cordasic N, Klanke B, Heusinger-Ribeiro J, Daniel C, Veelken R, Hartner A & Hilgers KF (2011). Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage. J Hypertens 29, 1602-1612.
21. Krag S, Danielsen CC, Carmeliet P, Nyengaard J & Wogensen L (2005). Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-β1-induced kidney disease. Kidney Int 68, 2651-2666.
22. Kvassman J-O & Shore JD (1995). Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic chromography. Fibrinolysis 9, 215-221.
23. Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME & Kitching AR (2007). Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 50, 1315-1326.
24. Lee HS, Park SY, Moon KC, Hong HK, Song CY & Hong SY (2001). mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis. Histopathology 39, 203-209.
25. Li Y, Kang YS, Dai C, Kiss LP, Wen X & Liu Y (2008). Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 172, 299-308.
26. Liu G, Kaw B, Kurfis J, Rahmanuddin S, Kanwar YS & Chugh SS (2003). Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest 112, 209-221.
27. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G & Eddy AA (2005). Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67, 2221-2238.
28. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH & Steffes MW (2004). Nephropathy in diabetes. Diabetes Care 27(Suppl 1), S79-S83.
29. Navarro-Muñoz M, Ibernon M, Pérez V, Ara J, Espinal A, López D, Bonet J & Romero R (2011). Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients. Nephrol Dial Transpant 26, 3914-3923.
30. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A & Hsueh WA (2005). Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67, 1297-1307.
31. Oda T, Jung YO, Kim HS, Cai X, López-Guisa JM, Ikeda Y & Eddy AA (2001). PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60, 587-596.
32. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S & Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345, 870-878.
33. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C & Fogo AB (2002). Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61, 2142-2148.
34. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M & Weitz JI (2000). Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 275, 19788-19794.
35. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA & Mundel P (2004). Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113, 1390-1397.
36. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EKO & Sraer JD (1990). Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 33, 55-60.
37. Scaffidi AK, Moodley YP, Weichselbaum M, Thompson PJ & Knight DA (2001). Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins. J Cell Sci 114, 3507-3516.
38. Senoo T, Hattori N, Tanimoto T, Furonaka M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Yokoyama A & Kohno N (2010). Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 65, 334-340.
39. Shankland SJ (2006). The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69, 2131-2147.
40. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI & Border WA (1995). Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 6, 286-294.
41. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC & Lawrence DA (2001). Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276, 8135-8141.
42. Vial D & McKeown-Longo PJ (2008). PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the αvβ5 and α5β1 integrins. J Cell Sci 121, 1661-1670.
43. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P & Reiser J (2008). Modification of kidney barrier function by the urokinase receptor. Nat Med 14, 55-63.
44. Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K, Kubo A, Akai Y, Toyoda M, Kanauchi M, Neilson EG & Saito Y (2009). Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 54, 653-664.
45. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI & Border WA (1996). Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49, 461-469.
46. Yamamoto T, Noble NA, Miller DE, Gold LI, Hishida A, Nagase M, Cohen AH & Border WA (1999). Increased levels of transforming growth factor-β in HIV-associated nephropathy. Kidney Int 55, 579-592.
47. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ & Floege J (2005). Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16, 1733-1741.
48. Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y & Epstein PN (2008). Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 19, 2077-2085.
49. Ziyadeh FN & Wolf G (2008). Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4, 39-45.